• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data. Read More

COCOON Dermatologic Regimen Improves QOL in EGFR+ Lung Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with lung cancer. Read More

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics. Read More

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC. Read More

COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC. Read More

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • Oral safusidenib begins trial as maintenance for high-grade glioma
  • Outcomes of relapse after teclistamab therapy in multiple myeloma
  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT